PETV Gaining Momentum in Pet Therapeutics Market

Investment and Company Research
Opportunity Research
RESEARCH NOTE
 

icon Download Report in PDF Or Scroll down to read the complete report below.

PETVIVO HOLDINGS, INC.

PETV Gaining Momentum in Pet Therapeutics Market

Rob Goldman
[email protected]

June 19, 2020
 

PETVIVO HOLDINGS, INC. (OTC – PETV - $0.42)

Industry: Medical Technology Price Target: Under Review
   

COMPANY SNAPSHOT

INVESTMENT HIGHLIGHTS

PetVivo is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets. This approach accelerates the timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals. PETV recently exclusively licensed its mucoadhesive technology to a strategic partner, Emerald Organic Products, Inc., for use of CBD in the human nutraceutical market, and plans to license products in varying therapeutic categories.

 

KEY STATISTICS

 
Price as of 6/18/20 $0.42  
52 Wk High - Low $0.8778- $0.1222  
Est. Shares Outstanding 22.9M  
Market Capitalization $9.4M  
30-Day Average Volume 4,350  
Exchange: OTCQB  
 

COMPANY INFORMATION

PetVivo Holdings, Inc.
5251 Edina Industrial Blvd

Edina MN 55439
Phone: 952.405.6216
Website: www.PetVivo.com
Email: [email protected]


 

PETV is well-positioned to emerge as the standard of care for the treatment of osteoarthritis in dogs and horses, an unmet need representing an estimated $3.2B market.

PETV’s lead product, Kush®, is set for a second half 2020 launch, with pre-production runs beginning next month in the Company’s new in-house facility. In fact, Kush®  production capacity could reach 500,000 units per year.

Management has excelled at preparing the veterinary channel for the launch, during the current COVID-19 pandemic. PETV has already communicated with hundreds of veterinarians around the US and in some cases sent product samples for testing.

PETV just announced a key milestone event, which is a big plus for shareholders, in our view. Ahead of the Kush® pre-production, PETV entered into a convertible promissory note agreement with an investor totaling $600,000. While $300,000 (for 557K shares and warrants) has already been invested the remaining 50% tranche is due upon filing of the PETV 10-K, slated to be completed in the coming weeks. The notes bear 12.5% interest and mature in March 2021. Shares are convertible at $0.28 while warrants are exercisable at $0.35.

Our financial projections and price target are under review but we believe that PETV could generate  $10M+ in revenue sales in its first full year, which could support a valuation well past its 52-week high.    

RECENT TRADING HISTORY FOR PETV

(Source: www.Stockta.com)

Senior Analyst: Robert Goldman

Rob Goldman founded Goldman Small Cap Research in 2009 and has over 25 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification

I, Robert Goldman, hereby certify that the view expressed in this research report or article, accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

Disclaimer

This Opportunity Research report was prepared for informational purposes only.

Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select format reflects the Firm’s internally generated stock ideas along with economic and stock market outlooks. Opportunity Research reports, updates, notes, and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored micro-cap research ideas that typically carry greater risks than those stocks covered in the Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research reports on profiled stocks in the Opportunity Research format typically have a higher risk profile and may offer greater upside. Goldman Small Cap Research was not compensated for the production and distribution of this research note or associated press release. From 2016-2019, GSCR’s principal was compensated by Marble Arch Research Inc. to produce reports and updates on PETV on behalf of Marble Arch Research Inc. and under its banner. In the future, GSCR may be compensated by the Company or a third party for research report and press release production and distribution. All information contained in this research note was provided by the Company via filings, press releases or its website, or through our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This report does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com